<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37012065</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>428</StartPage><EndPage>435</EndPage><MedlinePgn>428-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2022-330709</ELocationID><Abstract><AbstractText Label="BACKGROUND">Phosphorylated-tau181 (p-tau181), a specific marker of Alzheimer's disease (AD) pathology, was found elevated in plasma but not in cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS). We expanded these findings in a larger patient cohort, exploring clinical/electrophysiological associations, prognostic value and longitudinal trajectories of the biomarker.</AbstractText><AbstractText Label="METHODS">We obtained baseline plasma samples from 148 ALS, 12 spinal muscular atrophy (SMA), and 88 AD patients, and 60 healthy controls. Baseline CSF and longitudinal plasma samples were from 130 and 39 patients with ALS. CSF AD markers were measured with the Lumipulse platform, and plasma p-tau181 with SiMoA.</AbstractText><AbstractText Label="RESULTS">Patients with ALS showed higher plasma p-tau181 levels than controls (p&lt;0.001) and lower than AD participants (p=0.02). SMA patients had higher levels than controls (p=0.03). In patients with ALS, CSF p-tau and plasma p-tau181 did not correlate (p=0.37). Plasma p-tau181 significantly increased with the number of regions showing clinical/neurophysiological lower motor neurons (LMN) signs (p=0.007) and correlated with the degree of denervation in the lumbosacral area (r=0.51, p&lt;0.0001). Plasma p-tau181 levels were higher in classic and LMN-predominant than in bulbar phenotype (p=0.004 and p=0.006). Multivariate Cox regression confirmed plasma p-tau181 as an independent prognostic factor in ALS (HR 1.90, 95% CI 1.25 to 2.90, p=0.003). Longitudinal analysis showed a significant rise in plasma p-tau181 values over time, especially in fast progressors.</AbstractText><AbstractText Label="CONCLUSIONS">Plasma p-tau181 is elevated in patients with ALS, independently from CSF levels, and is firmly associated with LMN dysfunction. The finding indicates that p-tau181 of putative peripheral origin might represent a confounding factor in using plasma p-tau181 for AD pathology screening, which deserves further investigation.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Vacchiano</LastName><ForeName>Veria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-3607-2394</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mastrangelo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenesini</LastName><ForeName>Corrado</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiardi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avoni</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polischi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capellari</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liguori</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parchi</LastName><ForeName>Piero</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9444-9524</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Universit&#xe0; di Bologna, Bologna, Italy piero.parchi@unibo.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>BoReALS group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):409-410</RefSource><PMID Version="1">37012069</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALZHEIMER'S DISEASE</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">EMG</Keyword><Keyword MajorTopicYN="N">MOTOR NEURON DISEASE</Keyword><Keyword MajorTopicYN="N">SPINAL MUSCULAR ATRO</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Cinelli</LastName><ForeName>Franca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stasi</LastName><ForeName>Vitantonio Di</ForeName><Initials>VD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plasmati</LastName><ForeName>Rosaria</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pastorelli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quarta</LastName><ForeName>Cecilia Celidea</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milletti</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nasca</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santoro</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valeriani</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anzolin</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fantoni</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donadio</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vignatelli</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanzani-Maserati</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asioli</LastName><ForeName>Sofia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colombo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maselli</LastName><ForeName>Serena</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannoccaro</LastName><ForeName>Maria Pia</ForeName><Initials>MP</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37012065</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2022-330709</ArticleId><ArticleId IdType="pii">jnnp-2022-330709</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>